Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics

The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.

Subsidie
€ 4.420.511
2023

Projectdetails

Introduction

Our vision for a new type of cancer treatment is based on an implantable therapeutic system capable of programmable on-demand delivery of drugs directly to the tumor. We conceive an implantable iontronic switch (bioSWITCH) to enable a spatiotemporally controlled administration of highly potent chemotherapeutics, without the need for systemic administration of (pro)drugs or drug conjugates.

Technology Overview

This radically new technology will be realized by a combination of next-level tools. As a result, bioSWITCH can generate previously unobtainable discrete as well as continuous drug concentration profiles at the tumor site. This capability allows for the use of highly potent drugs that are otherwise not applicable due to high cytotoxicity.

Goals

The goal is to demonstrate the technology's potential to effectively interfere with tumor progression using a xenograft pancreas cancer mouse model. Efficiently shrinking tumors in size allows for surgical resection of previously non-operable tumors and dramatically increases survival rates.

Consortium

Our consortium of world-leading academics and pioneering SMEs will ensure the translation of this disruptive technology into the market to maximize the socioeconomic impact.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 4.420.511
Totale projectbegroting€ 4.420.511

Tijdlijn

Startdatum1-3-2023
Einddatum28-2-2026
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • LINKOPINGS UNIVERSITETpenvoerder
  • TAGWORKS PHARMACEUTICALS BV
  • TECHNISCHE UNIVERSITAET WIEN
  • SUPRAPOLIX BV
  • MEDIZINISCHE UNIVERSITAT GRAZ
  • OBOE IPR AB
  • HUN-REN TERMESZETTUDOMANYI KUTATOKOZPONT

Land(en)

SwedenNetherlandsAustriaHungary

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.

€ 2.606.250
EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

€ 2.966.695
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875
EIC Pathfinder

In-situ & operando organiC electrochemical transistors monitored by non-destructive spectroscopies for Organic cmos-like NeuromorphIc Circuits

ICONIC aims to advance implantable AI organic electronic devices for chronic disease management by investigating PMIECs, leading to smart drug-delivery systems with enhanced accuracy and safety.

€ 2.664.940
EIC Pathfinder

On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology

DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.

€ 3.018.312

Vergelijkbare projecten uit andere regelingen

ERC Starting...

Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision

Develop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies.

€ 1.496.795
ERC Proof of...

Preclinical validation and market analysis of a microMESH implant for brain cancer eradication

The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.

€ 150.000
ERC Consolid...

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

€ 1.993.875
ERC Consolid...

Unlocking a T cell-mediated Immune response in therapy-challenged Tumors

UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.

€ 2.000.000
ERC Starting...

Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision

Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.

€ 1.479.321